Target Audience
- Researchers, engineers, and professionals interested in the convergence of artificial intelligence and life sciences, as well as emerging trends in biotechnology R&D.
- Individuals interested in collaborative research among universities, companies, and nonprofit organizations, research funding models, and research organization management.
- Readers seeking to understand the achievements, challenges, and long-term societal impact of large-scale scientific research initiatives.
Summary
- Chan Zuckerberg Biohub (Biohub) is a nonprofit biomedical research organization established in 2016. Initially focused on collaboration among universities, it has evolved into an organization integrating AI, large-scale biological data, and experimental technologies.
- Beginning in 2021, Biohub expanded toward a nationwide research network, establishing new research hubs in Chicago and New York in 2023.
- In 2025, Biohub reorganized its research structure around the convergence of AI and biology. In 2026, it advanced international collaboration to build large-scale biological data infrastructure through the Virtual Biology Initiative.
- Biohub's distinctive characteristics include long-term research funding, interdisciplinary university collaboration, shared research technologies and data infrastructure, and a commitment to open science.
- Major challenges include the scientific reliability of AI models, the quality of large-scale biological data, financial and organizational sustainability, and translating fundamental research into clinical applications.
1. Introduction: What Is Chan Zuckerberg Biohub?
Chan Zuckerberg Biohub (hereafter "Biohub") is a nonprofit biomedical research organization established in 2016 by the Chan Zuckerberg Initiative (hereafter "CZI"), founded by Meta co-founder Mark Zuckerberg and pediatrician Priscilla Chan.
CZI was established in 2015 as a philanthropic organization addressing challenges in healthcare, education, and local communities. In science, it has articulated a long-term vision of helping to cure, prevent, or manage all diseases by the end of the 21st century. [1]
Biohub was created as a research organization to help realize this vision.
Initially, Biohub connected three universities—Stanford University, the University of California, Berkeley (UC Berkeley), and the University of California, San Francisco (UCSF)—to support ambitious, high-risk, long-term research that would be difficult to pursue within conventional university structures or research funding systems. [2]
Over the following decade, however, Biohub's role changed significantly.
Today, it has evolved into a research organization integrating AI, large-scale biological data, and advanced experimental and measurement technologies to develop foundational tools for disease prevention and treatment.
Importantly, Biohub's evolution has involved much more than expanding the number of research facilities.
Rather than merely funding external researchers, it has increasingly pursued an integrated approach to building research organizations, measurement instruments, datasets, and AI models.
Its development can be broadly divided into three phases:
- 2016–2021: Establishing a university-centered collaborative research model
- 2021–2024: Expanding into the multi-institutional Biohub Network
- 2025 onward: Transforming into an integrated AI and experimental science research infrastructure
The year 2025 represented a major strategic turning point, while 2026 marked the expansion of this new strategy into international scientific collaboration. [3][4][5]
This article examines Biohub's origins, organizational structure, research areas, achievements, and challenges, tracing its development from its establishment to the present.
The information presented is based on publicly available sources as of November 4, 2026.
2. The History of Biohub: From Its Founding to the Present
2.1. 2015: Establishment of the Chan Zuckerberg Initiative
In 2015, Mark Zuckerberg and Priscilla Chan established CZI.
CZI began as a philanthropic organization aiming to address long-term societal challenges through science and technology.
Its activities initially extended beyond scientific research to include education and support for local communities.
In science, CZI set a goal of advancing the technologies needed to understand, treat, and prevent diseases.
Underlying the creation of Biohub was the belief that funding individual research projects alone would be insufficient to achieve this goal.
It would also be necessary to create environments where researchers from different disciplines could collaborate continuously and to establish mechanisms for developing new scientific technologies. [1][2]
2.2. 2016: Establishment of the First Biohub
On September 23, 2016, CZI announced the establishment of the first Biohub.
At its founding, CZI committed $600 million in funding. [2]
The first Biohub was established in the San Francisco Bay Area, bringing together researchers and engineers from Stanford University, UCSF, and UC Berkeley.
Stephen Quake and Joe DeRisi served as its initial co-leaders.
Two major research projects were established:
- Human Cell Atlas-related research: Research to characterize the types and states of human cells and organize foundational information for the life sciences.
- Infectious disease research: Research to develop technologies for detecting and analyzing pathogens and improving our understanding of infectious diseases.
From the outset, Biohub emphasized overcoming institutional boundaries between universities rather than simply distributing research funding.
2.3. 2017–2020: Establishing the Research Support Model
In 2017, 47 researchers from the three participating universities were selected for a research support program, with $50 million in funding announced over five years. [2]
The program emphasized researchers' intellectual freedom, enabling them to pursue exploratory projects that might be difficult to fund through conventional grant programs.
At the same time, Biohub advanced the development of shared technologies, including tools for cellular analysis and pathogen detection.
When the COVID-19 pandemic began in 2020, Biohub also contributed to diagnostic testing technologies and infectious disease research.
During this period, Biohub established two complementary functions: supporting cross-university scientific research and developing research technologies within its own organization.
2.4. 2021: Announcement of the Biohub Network
In December 2021, CZI announced plans to expand the Biohub model across the United States. [3]
The initiative envisioned research hubs jointly established by multiple universities, each addressing major scientific challenges over a period of approximately 10 to 15 years.
CZI also announced that the operation of the original Biohub would be extended through 2031.
This represented an effort to apply the research model established at the first Biohub to additional regions and scientific disciplines.
Rather than concentrating research capabilities within a single university, the concept was to combine the strengths of universities and research institutions in different regions to form a network capable of addressing major scientific challenges.
2.5. 2023: Expansion to Chicago and New York
In 2023, new Biohubs were established in Chicago and New York. [6]
Biohub Chicago brought together three universities:
- University of Chicago
- Northwestern University
- University of Illinois Urbana-Champaign
Its primary research focus is the development of technologies to measure and understand inflammation.
Particular emphasis is placed on biosensors and other technologies capable of continuously monitoring changes in inflammation within living organisms.
Meanwhile, Biohub New York brought together three universities:
- Columbia University
- Rockefeller University
- Yale University
Its principal research focus is cellular engineering.
In particular, it aims to engineer immune cells capable of detecting signs of disease within the body, potentially functioning like a "cellular endoscope."
Biohub New York was announced in 2023, and an official opening event was held in 2024.
Through this expansion, Biohub evolved from a single research institute into a multi-hub research network leveraging the specialized strengths of universities in different regions.
2.6. 2025: Strategic Focus on AI and Biology
The year 2025 marked a significant shift in Biohub's research strategy.
In February, CZI described its increasing focus on scientific research.
On November 6 of that year, it announced a plan to integrate previously separate scientific research teams around Biohub. [4]
The reorganization identified four Grand Challenges centered on the convergence of AI and biology:
- AI models of cells
- Advanced imaging
- Measurement of inflammation
- Reprogramming immune cells
This represented a strategic transformation from a university-centered collaborative research institute toward a research organization integrating AI, data, and experimental science.
2.7. 2026: Launch of the Virtual Biology Initiative
In April 2026, Biohub announced the Virtual Biology Initiative. [5]
Under this initiative, Biohub committed to investing $500 million.
The objective is to build a large-scale, openly accessible data infrastructure that enables AI systems to predict biological phenomena.
In October 2026, the participation of additional organizations was announced, including the U.S. Department of Energy (DOE), the National Institutes of Health (NIH), Google DeepMind, Isomorphic Labs, and Meta.
By that point, the total value of committed financial and research resources associated with the initiative had reached a reported $1.8 billion. [7]
However, this $1.8 billion includes not only new funding but also existing data resources, computing resources, and technologies.
It should therefore not be interpreted as entirely new cash funding.
These developments demonstrate Biohub's expanding ambition: not merely to produce scientific results within a single organization, but to establish shared data and technology infrastructure for research on a global scale.
3. Biohub's Organizational Structure and Research Locations
3.1. The Relationship Between CZI and Biohub
Understanding Biohub requires distinguishing its role from that of CZI.
CZI is responsible for the broader philanthropic strategy, allocation of resources, and support for scientific activities.
Biohub, by contrast, is a nonprofit research organization that directly conducts biomedical and life sciences research.
Their functional relationship can be summarized as follows:
| Organization or Function | Primary Role |
|---|---|
| CZI | Philanthropic strategy, research funding, and strategic support |
| Biohub | Conducting biomedical and life sciences research, integrating research teams, combining AI and biology |
| Universities and research institutions | Collaborative research, scientific expertise, and researcher participation |
| Research facilities and technologies | Experimentation, measurement, imaging, and technology development |
| Data and AI infrastructure | Large-scale data organization, computing, and model development |
| External partners | Collaboration with governments, companies, and international research organizations |
This table summarizes functional relationships rather than a formal legal organizational chart or ownership structure.
At its founding, Biohub was established as an independent research institute with governance participation from the three universities, while CZI served as its financial supporter.
Following the 2025 reorganization, Biohub was positioned as the central organization responsible for executing CZI's scientific research strategy. [4]
3.2. San Francisco: The Core of the Original Biohub Model
Biohub San Francisco was established in 2016 as the first research hub.
Built on collaborations with Stanford, UC Berkeley, and UCSF, it has pursued research in cell biology, infectious diseases, and technology development.
In 2025, plans were announced to integrate it with the advanced biological imaging institute.
This hub has played a central role in demonstrating the Biohub research model and establishing the foundation for its subsequent network expansion. [2][4]
3.3. Chicago: Real-Time Measurement of Inflammation
Biohub Chicago was established in 2023.
Its participating universities are the University of Chicago, Northwestern University, and the University of Illinois Urbana-Champaign.
Its primary research focus is developing technologies for measuring inflammation in real time.
Inflammation is associated with many diseases, but accurately monitoring inflammatory conditions as they change over time within living organisms remains challenging.
To address this problem, Biohub Chicago is developing biosensors and other measurement technologies capable of continuously monitoring inflammation inside the body.
Its research is relevant not only to examining diseases after they have developed but also to identifying early changes that may contribute to disease onset or progression.
3.4. New York: Engineering Immune Cells
Biohub New York was announced in 2023, with an official opening event held in 2024.
Its participating universities are Columbia, Rockefeller, and Yale.
Its primary research focus is the measurement and engineering of immune cells.
The goal is to modify immune cells so that they can function as sensors capable of detecting abnormalities inside the body.
Beyond detection, the long-term research vision includes using engineered immune cells as therapeutic tools that can act on diseases.
This approach is also related to the concept of a Virtual Immune System.
3.5. Redwood City: Advanced Biological Imaging
In Redwood City, advanced microscopy technologies have been developed through the Chan Zuckerberg Institute for Advanced Biological Imaging.
One representative research area is cryo-electron tomography (cryoET).
This technology enables high-resolution observation of molecular structures and the internal architecture of cells.
In 2025, plans were announced to integrate this activity with the San Francisco research organization. [4]
Its main research objective is the high-resolution visualization of molecular and cellular structures.
3.6. Other Research Partnerships
Biohub has also announced research partnerships in Seattle and relationships with Harvard University's Kempner Institute.
However, these collaborations do not necessarily have the same organizational status as independent Biohub research institutes.
When evaluating Biohub's activities, it is important to distinguish among independent research hubs, collaborative research networks, and partnerships focused on technology or data.
3.7. Scale of Research Funding
One distinctive feature of Biohub is its large-scale, long-term research funding.
Major publicly announced financial commitments include the following:
| Initiative | Announcement | Amount |
|---|---|---|
| Original Biohub | 2016 | $600 million |
| Initial investigator support program | 2017 | $50 million |
| Biohub Chicago | 2023 | $250 million from CZI and $25 million from the state |
| Biohub New York | 2023 | $250 million from CZI, plus $10 million each from the state and city |
| Virtual Biology Initiative | April 2026 | $500 million from Biohub |
| Expansion of the Virtual Biology Initiative | October 2026 | $1.8 billion in combined commitments and resources |
Sources include official announcements from Biohub and CZI, along with related reporting. [2][5][6][7]
Importantly, these amounts should not simply be added together to calculate Biohub's cumulative investment.
The 2017 investigator program was part of the original Biohub initiative, while the $1.8 billion announced in October 2026 includes existing commitments and research resources.
4. What Makes Biohub Different from Conventional Research Institutions?
Biohub's defining characteristics extend beyond the scale of its financial resources.
More importantly, they concern how scientific research is organized and conducted.
4.1. Collaboration Across Universities and Disciplines
Biohub emphasizes building teams that cross disciplinary boundaries, bringing together life sciences, medicine, computer science, physics, and engineering.
It provides organizational support for sharing facilities and conducting collaborative research that would be difficult for individual universities or laboratories to accomplish independently.
By combining expertise from multiple disciplines, this model creates opportunities to address complex biological challenges.
4.2. Research Horizons of 10 to 15 Years
The Biohub Network is designed around scientific challenges that may require 10 to 15 years of sustained research. [3]
A distinctive feature is its willingness to support ambitious, high-risk projects that may be difficult to evaluate based solely on short-term publication output or near-term commercialization prospects.
Conventional competitive grants, often covering approximately three to five years, may not always provide the continuity needed for long-term infrastructure development or large-scale data generation.
Biohub's model is intended to complement such funding mechanisms.
4.3. Developing Research Technologies, Not Just Scientific Findings
Biohub invests not only in discovering new scientific knowledge but also in developing the technologies that make such discoveries possible.
Examples include:
- New measurement instruments
- Cellular analysis methods
- Large-scale databases
- Advanced imaging technologies
- AI models
- Platforms for sharing research data
These technologies are intended to become shared infrastructure accessible not only to Biohub researchers but also to the broader scientific community.
4.4. An Integrated Cycle of Data, Experiments, and AI
Since 2025, the integration of experimental science and AI has become particularly important.
The underlying concept is an iterative research cycle:
- Generate large-scale biological datasets through experiments and measurements.
- Train AI models using the generated data.
- Use AI models to predict biological phenomena.
- Test those predictions through further experiments.
- Incorporate the experimental results into new datasets to improve the models.
By repeating this cycle, Biohub aims to improve the efficiency of scientific research, from hypothesis generation to experimentation and validation.
A major strength of the Biohub model is that it can develop not only computational capabilities but also the experimental facilities and measurement technologies needed to generate training data.
4.5. Commitment to Open Science
Biohub emphasizes making research findings available to external scientists and enabling researchers worldwide to use its technologies and datasets.
Representative initiatives include:
- CELL×GENE
- CryoET Data Portal
- Large-scale cellular and molecular datasets
- Publicly released AI models
Through these platforms, Biohub aims to ensure that scientific outputs are not confined to its own research organization but can be reused by other institutions.
4.6. Comparison with Conventional University Research Models
The differences between Biohub and a typical university-centered research model can be summarized as follows:
| Dimension | Conventional University-Centered Research | Biohub Model |
|---|---|---|
| Research questions | Topics defined by individual researchers or laboratories | Shared, long-term Grand Challenges |
| Funding | Combination of competitive research grants | Large-scale philanthropic funding as a foundation |
| Teams | Often organized by university or laboratory | Designed across universities and disciplines |
| Technology development | Technologies needed for individual projects | Shared research infrastructure as a primary objective |
| Data utilization | Collected and analyzed for individual projects | Integrated large-scale generation, sharing, and AI training |
| Outputs | Publications, discoveries, and researcher development | Publications and discoveries, plus datasets, instruments, and platforms |
This comparison illustrates typical research management differences.
Not every university research project or Biohub initiative fits neatly into these categories.
5. Biohub's Major Research Areas and Achievements
Following the organizational restructuring announced in November 2025, Biohub identified four Grand Challenges as the central pillars of its research strategy. [4]
5.1. Virtual Cell: AI Models of Cells
Virtual Cell research aims to represent genes, proteins, cellular states, and other biological information using AI models.
The goal is to predict how cells respond to stimuli, genetic changes, and other interventions.
In the longer term, such models may allow researchers to evaluate hypotheses computationally before conducting physical experiments.
Related platforms and projects include CELL×GENE, cellular AI models, and the Billion Cells Project.
This research extends beyond understanding the components of cells toward predicting how changes to those components affect the behavior of the cell as a whole.
5.2. Advanced Imaging
Advanced Imaging focuses on technologies for visualizing the structures and dynamics of cells, from molecular to tissue scales.
Major areas include:
- Cryo-electron tomography (cryoET)
- New microscopy technologies
- AI-based image analysis
- Technologies for understanding three-dimensional molecular and cellular structures
Representative platforms and technologies include the CryoET Data Portal and laser phase plate technology.
These technologies aim to reveal detailed cellular structures that have been difficult to observe using conventional methods.
5.3. Inflammation: Continuous Measurement of Inflammatory Processes
Inflammation is associated with many diseases.
However, continuously measuring inflammatory states as they change over time inside living organisms remains difficult.
Biohub Chicago is developing small sensors and other technologies to continuously measure conditions within cells and tissues.
Representative technologies include in vivo protein sensors and measurement devices.
These technologies are intended to help researchers understand diseases as dynamic processes rather than relying solely on measurements taken at individual points in time.
5.4. Immune Cell Engineering: Reprogramming Immune Cells
This research area explores how immune cells can be used as sensors for detecting abnormalities in the body and as potential tools for treating disease.
It is a major focus of Biohub New York and is related to the Virtual Immune System concept.
Research objectives include:
- Early detection of diseases
- Regulation of immune responses
- Applications in cell-based therapies
By leveraging immune cells' ability to move throughout the body and detect abnormal conditions, researchers aim to develop new diagnostic and therapeutic technologies.
5.5. Publicly Available Scientific Outputs and Projects
Biohub has developed or supported a range of data platforms, research technologies, and AI models.
Representative examples include:
| Output or Project | Description | Status as of 2026 |
|---|---|---|
| CELL×GENE | Platform for exploring and visualizing single-cell data | Public research infrastructure |
| Tabula Sapiens and related cell atlases | Large-scale molecular information about organs and cell types | Foundational research data |
| CryoET Data Portal | Platform for sharing 3D molecular and cellular structural data | Public data infrastructure |
| COVID-19 and MIS-C research | Investigation of immune mechanisms associated with pediatric inflammatory diseases | Research findings on disease mechanisms |
| Billion Cells Project | Initiative aiming to generate data at the scale of one billion cells | Ongoing project launched in 2025 |
| VariantFormer, CryoLens, and scLDM | AI models related to genetic variants, structural imaging, and single-cell data | Research models released in 2025 |
These outputs are not all at the same stage of maturity.
Public data platforms such as CELL×GENE and the CryoET Data Portal already represent usable research infrastructure.
By contrast, disease prediction through Virtual Cell models and the use of engineered immune cells for disease prevention or treatment should be distinguished as long-term research objectives rather than established clinical outcomes.
6. The Virtual Biology Initiative: A New Phase in 2026
The Virtual Biology Initiative is particularly important for understanding Biohub's direction in 2026. [5]
The initiative aims to establish large-scale biological data infrastructure needed to enable AI-based prediction of biological phenomena.
6.1. The $500 Million Commitment
In April 2026, Biohub announced a commitment of $500 million to the Virtual Biology Initiative.
The announced allocation was as follows:
| Investment Area | Amount | Share |
|---|---|---|
| Measurement technologies, data generation, and related activities | $400 million | 80% |
| Support for international data generation activities | $100 million | 20% |
| Total | $500 million | 100% |
This allocation indicates that Biohub is emphasizing not only AI model development but also the experimental and measurement technologies needed to generate high-quality training data.
Biohub has stated that developing accurate predictive models of cells will require orders of magnitude more biological data than are currently available. [5]
6.2. Expansion of International Collaboration in October 2026
In October 2026, the Virtual Biology Initiative expanded its participating organizations and committed research resources. [7]
Collaborating research organizations include:
- Allen Institute
- Arc Institute
- Broad Institute
- Wellcome Sanger Institute
- Human Cell Atlas
Additional organizations announced as participants in October 2026 included:
- U.S. Department of Energy (DOE)
- National Institutes of Health (NIH)
- Google DeepMind
- Isomorphic Labs
- Meta
At that point, the total value of related financial commitments and resources across participating organizations was reported as $1.8 billion.
However, this figure includes existing datasets, computing resources, technologies, and other contributions, in addition to new financial investments.
Therefore, the $500 million commitment from Biohub and the $1.8 billion figure should not be added together as independent new funding commitments.
6.3. Why Is International Data Infrastructure Necessary?
To predict biological phenomena using AI, models must learn from diverse cells, tissues, genetic changes, and responses to external stimuli.
However, individual research institutions face limitations in the scale and diversity of the data they can independently collect.
Biohub is therefore collaborating with international research organizations to build large-scale, reusable shared data infrastructure.
This can be understood as a shift away from data collection conducted primarily within individual research institutions toward a model in which the broader scientific community jointly generates and shares data needed for AI training.
Biohub is expanding its role from an organization that produces scientific findings into one that builds shared data infrastructure for the scientific community.
7. Challenges Facing Biohub
Biohub has developed a research model that combines substantial funding, highly skilled researchers, and advanced technologies.
At the same time, this model faces scientific, technological, and organizational challenges.
The following discussion distinguishes documented developments from risks that can be inferred from the structure of the research model.
7.1. Scientific and Technological Challenges
The principal scientific and technological challenges include:
| Challenge | Description | Importance |
|---|---|---|
| Insufficient biological data | Limited ability to fully measure conditions inside living organisms, temporal changes, and responses to external stimuli | High |
| Predictive performance of AI models | Whether models can make accurate predictions for cells and disease conditions not represented in training data | High |
| Experimental reproducibility | Data biases and measurement variability arising from differences among institutions and instruments | High |
| Translation into clinical applications | Whether cellular models can lead to diagnostic technologies, pharmaceuticals, or treatments | High |
| Computing and operational costs | Whether large-scale experiments, AI training, and data maintenance can be financially sustained over time | Medium–High |
These importance ratings are analytical assessments from a research strategy perspective, not official Biohub evaluations.
One particularly significant challenge is generating sufficient quantities of accurate biological data across diverse conditions, rather than focusing only on AI algorithms.
Biohub's investment in large-scale data generation through the 2026 Virtual Biology Initiative reflects its recognition of this challenge. [5]
Furthermore, there is a substantial validation gap between demonstrating strong AI performance in laboratory settings and accurately predicting human diseases for clinical use.
7.2. Dependence on Major Philanthropic Funding and Long-Term Continuity
One of Biohub's strengths is CZI's ability to make large-scale, long-term investments.
However, this also creates a risk of dependence on a particular funding organization.
Changes in the strategic priorities of CZI or its founders may significantly affect research priorities and staffing.
In fact, CZI clarified its increasing focus on scientific research in 2025, and reports in January 2026 indicated that approximately 70 positions were eliminated. [8]
This does not mean that Biohub's research activities stopped.
However, it demonstrates that organizational restructuring associated with strategic prioritization has occurred.
Sustaining long-term research therefore requires not only sufficient financial resources but also mechanisms for retaining research organizations and scientific talent over extended periods.
7.3. Balancing Researcher Autonomy with Organization-Wide Priorities
The original Biohub model placed considerable emphasis on researcher autonomy.
A defining characteristic was enabling researchers to pursue original ideas that might be difficult to support through conventional grant programs.
Today, however, Biohub is moving toward an integrated research organization centered on four Grand Challenges. [4]
This approach offers the advantage of concentrating resources on major scientific problems.
At the same time, the organization must balance unified strategic priorities with researchers' freedom to explore unconventional ideas.
Maintaining exploratory research that may lead to unexpected discoveries will remain an important research management challenge.
7.4. Balancing Open Science with Corporate Partnerships
Biohub places a strong emphasis on making research data and AI models publicly accessible.
At the same time, collaborations announced in 2026 involve companies with substantial AI development capabilities, including Meta, Google DeepMind, and Isomorphic Labs. [7]
Such partnerships make several governance questions particularly important:
- Conditions governing the use of research data
- Intellectual property arrangements with corporate partners
- Access to publicly released models
- Commercial use of scientific findings
- Independence of research activities
These are governance issues that warrant continued attention.
They do not imply that specific inappropriate practices have been established.
7.5. Evaluating Long-Term Societal Impact
Biohub has produced concrete outputs in the form of research data, technologies, and scientific platforms.
However, its ultimate vision of helping prevent and treat diseases is inherently long-term.
Evaluating Biohub's impact therefore requires more than counting publications or released AI models.
Relevant measures include:
- Use of data and technologies by external researchers
- Independent validation of research findings
- Contributions to pharmaceutical development
- Applications in diagnostic and therapeutic technologies
- Medical outcomes that ultimately reach patients
It will be important to evaluate continuously how much Biohub's infrastructure contributes to progress across biomedical research.
7.6. Resource Allocation Across CZI
CZI's increasing focus on science provides Biohub with the advantage of concentrated research resources.
However, from the perspective of CZI as a whole, this also represents a shift of resources away from programs related to social policy, education, and local communities.
External reporting, including coverage by the Associated Press, has raised questions about the effects of this strategic shift on previous grant recipients and the narrowing of supported activities.
Therefore, evaluating Biohub's success also involves considering how CZI allocates its philanthropic resources across different societal priorities.
8. How Should Biohub's Evolution Be Evaluated?
Biohub's development can be divided into three major phases.
8.1. Phase One: Connecting Researchers and Universities (2016–2021)
The first phase centered on the combination of:
Funding × Outstanding Researchers × University Collaboration
During this period, Biohub focused on reducing constraints associated with university structures and conventional research funding systems.
Its objective was to create an environment in which researchers could pursue ambitious scientific challenges.
Support for individual researchers and organizational mechanisms enabling university collaboration were its defining features.
8.2. Phase Two: Building a Network of Specialized Research Hubs (2021–2024)
The second phase centered on the combination of:
Specialized Research Hubs × Long-Term Challenges × Research Technologies
Biohub expanded the model established in San Francisco to Chicago and New York.
By assigning major scientific challenges to individual hubs and leveraging the specialized expertise of regional universities, it expanded the scope of its research activities.
This phase represented a transition from a single research institute to a network of specialized research organizations.
8.3. Phase Three: Integrating AI and Experimental Science (2025 Onward)
The third phase centers on the combination of:
Experimentation and Measurement × Large-Scale Data × AI Models
The objective is to scale and automate research capabilities and accelerate biomedical discovery.
An important element is the continuous cycle of testing AI-generated predictions through experiments and using the resulting data to improve AI models.
In this phase, Biohub's central role extends beyond university collaboration to the integration of measurement technologies, computing resources, data infrastructure, and AI model development.
8.4. The Common Principle Across All Three Phases
A consistent theme throughout Biohub's evolution is its ambition to create new mechanisms for advancing scientific research, rather than merely distributing funding to existing institutions.
However, the current research model requires substantial investment in facilities, people, data, and computing resources.
As the organization expands, the complexity of research management and operations also increases.
Biohub must therefore maintain both the freedom required for long-term scientific exploration and the coordination needed to address major scientific challenges at an organizational level.
9. What to Watch Going Forward
When evaluating Biohub beyond 2026, it will be important to examine not only the scale of its funding or the establishment of new research organizations but also the scientific results generated by its infrastructure.
Key indicators include:
| Area to Monitor | Key Questions |
|---|---|
| Virtual Cell performance | How accurately can models predict previously unseen genetic interventions, drug responses, and cellular states? |
| Data accessibility | What are the scale, quality, usage conditions, and external reuse of generated datasets? |
| Automation and research efficiency | To what extent does AI contribute to experimental design, analysis, and hypothesis generation? |
| University collaboration | Are research participation, scientific output, and independent evaluation expanding? |
| Clinical translation | Are there concrete examples of research contributing to new diagnostic or therapeutic approaches? |
| Financial and organizational stability | Are long-term commitments being fulfilled, researchers being retained, and research activities sustained? |
Of particular importance is whether the Virtual Biology Initiative can progress beyond generating large datasets to enabling third-party researchers to use those datasets to make new scientific discoveries.
Another key question is whether AI models can accurately predict cellular behavior under biological conditions not represented in their training data.
Demonstrating such capabilities would make it possible to evaluate more concretely the value of the research infrastructure Biohub is developing.
10. Overall Assessment and Conclusion
Biohub's strengths extend well beyond its substantial financial resources.
Its distinctive feature is the integration of long-term funding, collaboration with leading universities, advanced measurement technologies, AI-driven experimental science, and open research infrastructure into a unified scientific strategy.
At the same time, this research model has structural weaknesses and risks.
These include dependence on a particular funding organization, the need to sustain substantial investments, scientific validation of AI models, balancing long-term research with shorter-term outcomes, and the distance between fundamental discoveries and clinical implementation.
These considerations can be summarized as follows:
| Evaluation Dimension | Assessment |
|---|---|
| Strengths | Large-scale long-term funding, university collaboration, advanced measurement technologies, integration of experiments and AI, open science |
| Structural weaknesses and risks | Funding dependence, investment scale, model validation, organizational management, and challenges in clinical translation |
| Factors determining future success | Whether publicly available data and AI models enable reproducible discoveries outside Biohub and contribute to the development of diagnostic and therapeutic technologies |
Biohub can now be understood as having evolved beyond the conventional philanthropic model of allocating research grants into a nonprofit organization that builds research infrastructure, developing advanced scientific technologies and AI platforms and making them available to researchers worldwide.
However, its AI-centered strategy, introduced primarily during 2025 and 2026, is still relatively new.
While progress in infrastructure development and resource commitments is already visible, considerably more time and independent validation will be required before concluding that these efforts have produced transformative advances in disease prevention or treatment.
Biohub's approximately ten-year history can be understood as a continuing effort to explore new organizational models for scientific research.
It began with collaboration among universities, expanded into a network of specialized research hubs, and is now moving toward the integration of AI and experimental science.
What makes this development especially instructive is not simply the availability of abundant research funding.
Rather, it is the way Biohub combines university collaboration, long-term scientific challenges, shared research facilities and data infrastructure, and AI-driven research efficiency into a coherent organizational strategy.
Ultimately, Biohub's success will not be determined solely by whether it can build large-scale AI models.
Its long-term value will depend on whether those models demonstrate scientifically validated predictive capabilities and generate sustainable benefits for medicine and society.
References
[1] Chan Zuckerberg Initiative, "Chan Zuckerberg Initiative," CZI Official Website. https://chanzuckerberg.com/
[2] Chan Zuckerberg Biohub, "CZI Announces the Chan Zuckerberg Biohub," Biohub, September 2016. https://biohub.org/news/czi-announces-the-chan-zuckerberg-biohub/
[3] Chan Zuckerberg Initiative, "Chan Zuckerberg Initiative Announces 10-Year Effort to Develop Science and Technologies to Measure Human Biology in Action," CZI, 2021. https://chanzuckerberg.com/newsroom/chan-zuckerberg-initiative-announces-10-year-effort-to-develop-science-and-technologies-to-measure-human-biology-in-action/
[4] Chan Zuckerberg Biohub, "AI, Biology, Cure Disease," Biohub, November 2025. https://biohub.org/news/ai-biology-cure-disease/
[5] Chan Zuckerberg Biohub, "Virtual Biology Initiative," Biohub, April 2026. https://biohub.org/news/virtual-biology-initiative/
[6] Nature Biotechnology, "Chan Zuckerberg Hubs Multiply," Nature Biotechnology, 2023. https://www.nature.com/articles/s41587-023-02039-5
[7] Chan Zuckerberg Biohub, "Virtual Biology Initiative Expansion," Biohub, October 2026. https://biohub.org/news/virtual-biology-initiative-expansion/
[8] Fortune, "Chan Zuckerberg Initiative Layoffs: All In on AI Biomedical Research," Fortune, February 2026. https://fortune.com/2026/02/01/chan-zuckerberg-initiative-layoffs-all-in-on-ai-biomedical-research/